Cham­pi­oned by Ab­b­Vie, im­muno-neu­rol­o­gy play­er Alec­tor maps $150M IPO

En­dorsed by Ab­b­Vie, and un­der the lead­er­ship of Genen­tech vet­er­an Arnon Rosen­thal, San Fran­cis­co-based biotech Alec­tor has chart­ed a path to­ward a $150 mil­lion IPO, as it de­vel­ops a crop of drugs de­signed to weaponize the im­mune sys­tem to fight neu­rode­gen­er­a­tive dis­eases, such as Alzheimer’s where re­cent R&D has fo­cused — large­ly in vain — on elim­i­nat­ing tox­ic pro­teins such as amy­loid be­ta.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER